The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices
Abstract
CONTEXT: Medical devices are common in clinical practice and have important effects on morbidity and mortality, yet there has not been a systematic examination of evidence used by the US Food and Drug Administration (FDA) for device approval. OBJECTIVES: To study premarket approval (PMA)--the most stringent FDA review process--of cardiovascular devices and to characterize the type and strength of evidence on which it is based. DATA SOURCES AND STUDY SELECTION: Systematic review of 78 summaries of safety and effectiveness data for 78 PMAs for high risk cardiovascular devices that received PMA between January 2000 and December 2007 [corrected]. DATA EXTRACTION: Examination of the methodological characteristics considered essential to minimize confounding and bias, as well as the primary end points of the 123 studies supporting the PMAs. RESULTS: Thirty-three of 123 studies (27%) used to support recent FDA approval of cardiovascular devices were randomized and 17 of 123 (14%) were blinded. Fifty-one of 78 PMAs (65%) were based on a single study. One hundred eleven of 213 primary end points (52%) were compared with controls and 34 of 111 controls (31%) were retrospective. One hundred eighty-seven of 213 primary end points (88%) were surrogate measures and 122 of 157 (78%) had a discrepancy between the number of patients enrolled in the study and the number analyzed. CONCLUSION: Premarket approval of cardiovascular devices by the FDA is often based on studies that lack adequate strength and may be prone to bias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Ethical and Scientific Implications of the Globalization of Clinical Research
Glickman, S. W., McHutchison, J. G., Peterson, E. D., Cairns, C. B., Harrington, R. A., Califf, R. M., & Schulman, K. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsb0803929 · Cited by 710
Rising, K., Bacchetti, P., & Bero, L. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050217 · Cited by 328
Cited by
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M., & Ross, J. S. (2014) · JAMA · doi:10.1001/jama.2013.282034 · Cited by 407
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Regulation of Medical Devices in the United States and European Union
Kramer, D. B., Xu, S., & Kesselheim, A. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmhle1113918 · Cited by 270
Medical Device Recalls and the FDA Approval Process
Zuckerman, D. M., Brown, P., & Nissen, S. E. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.30 · Cited by 265
Improving Medical Device Regulation: The United States and Europe in Perspective
SORENSON, C., & DRUMMOND, M. (2014) · The Milbank Quarterly · doi:10.1111/1468-0009.12043 · Cited by 170
Metadata
- Authors
- Dhruva, S. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-12-23
- Volume
- 302
- Issue
- 24
- Pages
- 2679
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2022102342
- Cited by
- 198
- References
- 3
- FWCI
- 38.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices. https://app.cochat.ai/papers/10.1001/jama.2009.1899
- The paper
- Dhruva, S. S. (2009). Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices. JAMA. https://doi.org/10.1001/jama.2009.1899
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.